Paper Details

  1. Home
  2. Paper Details

Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia.

Author: ChanOnyee, FradleyMichael, IsenalumheLeidy, NodzonLisa, Pinilla-IbarzJavier, ShamsSamantha, SweetKendra, TalatiChetasi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This retrospective study examined the survival outcomes and toxicities of 78 patients with chronic myeloid leukemia (CML) treated with ponatinib. It found that ponatinib was highly effective, with a response rate and 5-year overall survival higher than those observed in a clinical trial. However, cardiovascular adverse events (CAEs) were observed in 23.1% of patients, with arrhythmia and hypertension being the most common. The study suggests that dose adjustments and increased awareness of cardiotoxicities associated with ponatinib may help maximize its benefits.
Paper Details　
Original Abstract of the Article :
Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the real world is limited. In this retrospective study, we examined the survival outcomes and associated toxicities in 78 consecutive ponatinib-treated patients with chronic myeloid leukemia (CML) at the Moffitt ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7013263/

データ提供：米国国立医学図書館（NLM）

Navigating the Side Effects of Ponatinib in Chronic Myeloid Leukemia Treatment

The treatment of [chronic myeloid leukemia (CML)] has seen significant advancements, with [ponatinib] emerging as a powerful [therapeutic] option. This study investigates the [side effect profile] and [treatment outcomes] associated with [ponatinib] in [CML] patients. The authors delve into the [cardiovascular adverse events (CAEs)] associated with [ponatinib], analyzing data from a [retrospective study] of [CML] patients treated with [ponatinib]. The study aims to understand the [risk-benefit] profile of [ponatinib] and identify strategies to minimize [CAEs].

Understanding the Cardiovascular Risks of Ponatinib

The study revealed that [ponatinib] is associated with [cardiovascular adverse events (CAEs)], including [arrhythmia] and [hypertension]. The researchers discovered that [earlier] use of [ponatinib] at higher doses was associated with a [greater] risk of [CAEs]. However, the study also found that [adjusting the starting dose] and [increasing] [cardio-oncology referrals] were associated with a [reduction] in [CAEs].

Balancing the Risks and Benefits of Ponatinib Therapy

The study highlights the importance of careful [monitoring] and [dose management] when using [ponatinib] to treat [CML]. It underscores the need for [early identification] and [management] of [cardiovascular risk factors]. While [ponatinib] offers a [powerful] therapeutic option for [CML], it is crucial to weigh the [potential benefits] against the [potential risks] and work closely with your healthcare provider to ensure [safe and effective] treatment.

Dr. Camel's Conclusion

This study provides a [valuable] perspective on the use of [ponatinib] in the [treatment] of [CML]. The authors emphasize the importance of [understanding the side effects] and [monitoring] patients closely to minimize [cardiovascular risks]. As we explore the [desert] of [cancer research], we must continue to seek ways to improve the [safety and efficacy] of [cancer treatments], always mindful of the delicate balance between [benefits and risks].

Date :
  1. Date Completed 2021-05-14
  2. Date Revised 2021-09-25
Further Info :

Pubmed ID

32045474

DOI: Digital Object Identifier

PMC7013263

Related Literature

Article Analysis
・Side Effects of ponatinib・Effects of ponatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.